Bass makes another pass at Tecfidera patent

Hedge fund manager Kyle Bass filed a third patent challenge against multiple sclerosis (MS) drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB).

The Coalition for Affordable Drugs V, an entity associated with Bass, filed an inter partes review (IPR) petition with the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office challenging U.S. Patent No. 8,399,514, which covers Tecfidera and expires in 2028. The '514 patent is the last to expire among seven Orange Book-listed patents covering Tecfidera. ...